荷淋巴瘤裸鼠放射免疫治疗^(99m)Tc-Annexin Ⅴ凋亡显像的研究

Study on Apoptotic Imaging with ^(99m)Tc-Annexin Ⅴ in Mice Bearing Lymphoma After Radioimmunotherapy

探讨99mTc-Annexin Ⅴ凋亡显像在评价淋巴瘤131I-Rituximab放射免疫治疗疗效中的价值及其最佳显像时间。荷淋巴瘤裸鼠经肿瘤间质、尾静脉注射131I-Rituximab治疗后不同时间点进行99mTc-Annexin Ⅴ凋亡显像,并分离解剖肿瘤组织进行流式细胞术和免疫组织化学检查,根据其与凋亡显像的吻合程度确定显像最佳时间。结果显示:131I-Rituximab经肿瘤间质注射后24h、36h、48h、96h99mTc-Annexin Ⅴ凋亡显像肿瘤/非肿瘤组织摄取比(T/NT)分别为6.0±1.08、8.4±1.68、8.1±1.89、7.0±0.95,高于相同时间点静脉注射组(3.4±0.27、5.1±0.82、6.7±0.58、5.8±0.91),且均与相同时间点细胞凋亡率、bax/bcl-2变化基本一致。结论:99mTc-Annexin Ⅴ凋亡显像作为无创性手段,能有效监测淋巴瘤131I-Rituximab放射免疫治疗后细胞凋亡情况,且放射免疫治疗后36h^48h是凋亡显像较佳时间。

To investigate the reliability of apoptotic imaging with 99mTc-Annexin Ⅴ to reflect the apoptosis of lymphoma cells after radioimmunotherapy with 131I-Rituximab and to select the optimal time point for apoptotic imaging.99mTc-Annexin Ⅴ apoptotic imaging in mice bearing lymphoma were done respectively at different time points after administration of 131I-Rituximab interstitially or intravenously.Mice were sacrificed and tumors were separated for flow cytometry and immunohistochemistry examinations after imaging.The results showed that the Tumor to Non-tumor ratio（T/NT） in mice were 6.0±1.08,8.4±1.68,8.1±1.89 and 7.0±0.95 respectively based on 99mTc-Annexin Ⅴ apoptotic images at 24h,36h,48h and 96h post radioimmunotherapy.The N/NT ratio in mice groups with interstitial injection of 131I-Rituximab were higher that of in the intravenous injection group.The change tendency of T/NT on apoptotic imaging was found almost the same with tumor cell apoptosis rate and bax/bcl-2 ratio.99mTc-Annexin Ⅴ apoptotic imaging can be served as one safe and effective method to monitor lymphoma cell apoptosis post 131I-Rituximab radioimmunotherapy.The imaging time points ranging from 36 to 48 hours post radioimmunotherapy will be preferred.